DGXQuest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. 10-K, Item 1
- Employees
- 57,000
- Headquarters
- Secaucus, NJ
- CEO
- J. E. Davis
- Next results
- around Jan 11, 2027
What DGX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Facts only; most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans adopted or ended
10 plans still running: Karthik Kuppusamy, Michael J. Deppe, Patrick Plewman, James E. Davis, Cathy Doherty, Gary Pfeiffer, Mike Prevoznik, Mark Delaney, Jim Davis.
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Karthik Kuppusamy SVP, Clinical Solutions |
Adopted 10b5-1 plan | Aug 26, 2026 | up to 1,000 | Apr 30, 2027 | 10-Q Oct 23, 2026 |
| Michael J. Deppe SVP, Corporate Controller and Chief Accounting Officer |
Adopted 10b5-1 plan | Aug 13, 2026 | up to 11,776 | Aug 13, 2027 | 10-Q Oct 23, 2026 |
| Patrick Plewman SVP, Diagnostic Services |
Adopted 10b5-1 plan | Aug 11, 2026 | up to 40,553 | Mar 31, 2027 | 10-Q Oct 23, 2026 |
| James E. Davis Chairman, Chief Executive Officer and President |
Adopted 10b5-1 plan | Aug 10, 2026 | up to 172,095 | Dec 31, 2027 | 10-Q Oct 23, 2026 |
| Cathy Doherty EVP |
Adopted 10b5-1 plan | Aug 3, 2026 | up to 34,252 | Apr 30, 2027 | 10-Q Oct 23, 2026 |
| Gary Pfeiffer Director |
Adopted 10b5-1 plan | May 29, 2026 | up to 1,203 | May 28, 2027 | 10-Q Jul 23, 2026 |
| Mike Prevoznik SVP, General Counsel |
Adopted 10b5-1 plan | May 29, 2026 | up to 31,956 | Mar 31, 2027 | 10-Q Jul 23, 2026 |
| Mark Delaney SVP, Chief Commercial Officer |
Adopted 10b5-1 plan | Apr 23, 2026 | up to 1,600 | Jan 22, 2027 | 10-Q Jul 23, 2026 |
| Karthik Kuppusamy SVP, Clinical Solutions |
Adopted 10b5-1 plan | Feb 26, 2026 | up to 8,147 | Feb 26, 2027 | 10-Q Apr 22, 2026 |
The company's descriptionName Title Type of Trading Arrangement Security Action Date of Action Duration of Trading Arrangement Aggregate Number of Securities Covered Karthik Kuppusamy SVP, Clinical Solutions Rule 10b5-1 plan to sell Common Stock Adoption February 26, 2026 February 26, 2026 to February 26, 2027* Up to 8,147* * Includes shares of common stock to be released from stock options. | |||||
| Cathy Doherty EVP, Regional Businesses |
Adopted 10b5-1 plan | Nov 14, 2025 | up to 37,423 | May 8, 2026 | 10-K Feb 26, 2026 |
The company's descriptionName Title Type of Trading Arrangement Security Action Date of Action Duration of Trading Arrangement Aggregate Number of Securities Covered Cathy Doherty EVP, Regional Businesses Rule 10b5-1 plan to sell Common Stock Adoption November 14, 2025 November 14, 2025 to May 8, 2026* Up to 37,423* * Includes shares of common stock to be released from (a) stock options and/or restricted stock units that are expected to vest and/or (b) performance share awards that may vest, subject to the satisfaction of the applicable performance metrics. The actual number of shares of common stock that will be released is not yet determinable and the actual number of shares of common stock that will be sold will be net of the number of shares withheld to satisfy employee tax withholding obligations. | |||||
| Jim Davis Chairman, CEO, and President |
Adopted 10b5-1 plan | Aug 26, 2025 | up to 95,093 | Dec 4, 2026 | 10-Q Oct 21, 2025 |
| Mark Delaney SVP and Chief Commercial Officer |
Adopted 10b5-1 plan | Aug 18, 2025 | up to 7,946 | May 11, 2026 | 10-Q Oct 21, 2025 |
| Michael Prevoznik SVP, General Counsel |
Adopted 10b5-1 plan | May 30, 2025 | up to 35,962 | Mar 31, 2026 | 10-Q Jul 23, 2025 |
| Karthik Kuppusamy SVP, Clinical Solutions |
Adopted 10b5-1 plan | May 1, 2025 | up to 10,479 | Oct 31, 2025 | 10-Q Jul 23, 2025 |
| Patrick Plewman SVP, Diagnostic Services |
Adopted 10b5-1 plan | May 1, 2025 | up to 48,470 | Mar 31, 2026 | 10-Q Jul 23, 2025 |
| Mark Delaney SVP, Chief Commercial Officer |
Adopted 10b5-1 plan | Feb 7, 2025 | up to 1,699 | Nov 11, 2025 | 10-Q Apr 23, 2025 |
| James E. Davis Chairman, Chief Executive Officer and President |
Adopted 10b5-1 plan | Oct 28, 2024 | up to 56,057 | Oct 28, 2025 | 10-K Feb 20, 2025 |
| Karthikeyan Kuppusamy SVP, Clinical Solutions |
Adopted 10b5-1 plan | Oct 28, 2024 | up to 2,833 | Jul 25, 2025 | 10-K Feb 20, 2025 |
| Michael Prevoznik SVP, General Counsel |
Adopted 10b5-1 plan | Aug 30, 2024 | up to 43,314 | 350 days | 10-Q Oct 23, 2024 |
| Cathy Doherty EVP, Regional Businesses |
Adopted 10b5-1 plan | Aug 27, 2024 | up to 43,558 | 360 days | 10-Q Oct 23, 2024 |
| Michael Deppe SVP, Corporate Controller and Chief Accounting Officer |
Adopted 10b5-1 plan | Aug 8, 2024 | up to 18,755 | 461 days | 10-Q Oct 23, 2024 |
| Karthikeyan Kuppusamy SVP, Clinical Solutions |
Adopted 10b5-1 plan | Nov 16, 2023 | up to 1,760 | 363 days | 10-K Feb 22, 2024 |
| Catherine Doherty SVP, Regional Businesses |
Adopted 10b5-1 plan | Aug 29, 2023 | up to 8,723 | 345 days | 10-K Feb 22, 2024 |
| Michael Prevoznik SVP, General Counsel |
Adopted 10b5-1 plan | Aug 7, 2023 | up to 6,876 | 220 days | 10-Q Oct 25, 2023 |
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 28, 2023.
Form 144 notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | Plewman Patrick Officer |
11,717 | $3,015,253 | Restricted Stock Vesting; Stock Option Exercise | adopted Aug 11, 2026 | none found |
| Nov 3, 2026 | Doherty Catherine T. Officer |
22,105 | $5,584,607 | Stock Option Exercise | adopted Aug 3, 2026 | 22,105 shares from Nov 3, 2026 |
| Oct 26, 2026 | PFEIFFER GARY M Director |
1,203 | $292,329 | Restricted Stock Vesting | adopted May 29, 2026 | 1,203 shares from Oct 26, 2026 |
| Sep 1, 2026 | Davis J. E. Officer, Director |
10,000 | $2,427,200 | Restricted Stock Vesting | adopted Aug 26, 2025 | 10,000 shares from Sep 1, 2026 |
| Aug 28, 2026 | PREVOZNIK MICHAEL E Officer |
22,677 | $5,513,082 | Stock Option Exercise | adopted May 29, 2026 | 22,677 shares from Aug 28, 2026 |
| Jul 28, 2026 | DELANEY MARK E Officer |
1,600 | $376,288 | Restricted Stock Vesting | adopted Apr 23, 2026 | 1,600 shares from Jul 28, 2026 |
| Jun 4, 2026 | KUPPUSAMY KARTHIK Officer |
8,147 | $1,629,400 | Stock Option Exercise | adopted Feb 26, 2026 | 8,147 shares from Jun 4, 2026 |
| Jun 1, 2026 | Davis J. E. Officer, Director |
10,000 | $1,941,360 | Restricted Stock Vesting | adopted Aug 26, 2025 | 10,000 shares from Jun 1, 2026 |
| Mar 5, 2026 | PREVOZNIK MICHAEL E Officer |
3,878 | $799,682 | Restricted Stock Vesting | adopted May 30, 2025 | none found |
| Mar 5, 2026 | Doherty Catherine T. Officer |
5,558 | $1,146,115 | Restricted Stock Vesting | adopted Nov 14, 2025 | none found |
| Mar 5, 2026 | Plewman Patrick Officer |
2,855 | $588,730 | Restricted Stock Vesting | adopted May 1, 2025 | none found |
| Mar 3, 2026 | Doherty Catherine T. Officer |
632 | $131,285 | Restricted Stock Vesting | adopted Nov 14, 2025 | none found |
| Mar 3, 2026 | PREVOZNIK MICHAEL E Officer |
526 | $109,266 | Restricted Stock Vesting | adopted May 30, 2025 | none found |
| Mar 3, 2026 | Plewman Patrick Officer |
410 | $85,169 | Restricted Stock Vesting | adopted May 1, 2025 | none found |
| Mar 2, 2026 | Davis J. E. Officer, Director |
10,000 | $2,125,200 | Restricted Stock Vesting | adopted Aug 26, 2025 | none found |
| Feb 19, 2026 | Plewman Patrick Officer |
958 | $196,227 | Restricted Stock Vesting | adopted May 1, 2025 | none found |
| Feb 19, 2026 | Doherty Catherine T. Officer |
1,433 | $293,521 | Restricted Stock Vesting | adopted Nov 14, 2025 | none found |
| Feb 19, 2026 | PREVOZNIK MICHAEL E Officer |
1,111 | $227,566 | Restricted Stock Vesting | adopted May 30, 2025 | none found |
| Feb 13, 2026 | Doherty Catherine T. Officer |
26,165 | $5,428,714 | Options Granted - 02/18/2020 | adopted Nov 14, 2025 | none found |
| Feb 10, 2026 | Plewman Patrick Officer |
5,662 | $1,155,048 | Option Granted - 02/17/2021 | adopted May 1, 2025 | none found |
| Nov 25, 2025 | Davis J. E. Officer, Director |
55,093 | $10,589,762 | Option Granted - 02/21/2017 | adopted Aug 26, 2025 | none found |
| Nov 25, 2025 | Gregg Vicky B Director |
1,250 | $239,700 | Dividend Reinvestment; Restricted Stock Vesting | none given | none found |
| Nov 18, 2025 | DELANEY MARK E Officer |
7,946 | $1,488,683 | Option Granted - 02/23/2023; Option Granted - 03/21/2022 | adopted Aug 18, 2025 | none found |
| Oct 22, 2025 | PFEIFFER GARY M Director |
1,482 | $270,317 | Restricted Stock Vesting | none given | none found |
From the Form 144 XML filed with the SEC, since Oct 22, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Work on DGX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DGX/export.csv") into a cell.